Cantor Fitzgerald Weighs in on IDYA FY2025 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for IDEAYA Biosciences in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($2.60) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.45) per share.

A number of other equities research analysts also recently weighed in on IDYA. Leerink Partnrs downgraded IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Stephens assumed coverage on IDEAYA Biosciences in a research report on Monday, November 18th. They set an “overweight” rating and a $51.00 target price on the stock. Oppenheimer reissued an “outperform” rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Finally, Wedbush reaffirmed an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of “Moderate Buy” and an average price target of $53.67.

IDEAYA Biosciences Stock Down 0.0 %

IDYA stock opened at $23.14 on Wednesday. IDEAYA Biosciences has a twelve month low of $22.10 and a twelve month high of $47.74. The company has a market cap of $2.00 billion, a PE ratio of -9.93 and a beta of 0.82. The business’s 50-day simple moving average is $25.79 and its 200 day simple moving average is $32.07.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.03. During the same period last year, the company earned ($0.46) EPS.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Allworth Financial LP raised its stake in shares of IDEAYA Biosciences by 800.0% in the third quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 800 shares during the last quarter. Covestor Ltd raised its position in IDEAYA Biosciences by 23,050.0% in the 3rd quarter. Covestor Ltd now owns 926 shares of the company’s stock worth $29,000 after purchasing an additional 922 shares during the last quarter. US Bancorp DE raised its position in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after purchasing an additional 689 shares during the last quarter. KBC Group NV raised its position in IDEAYA Biosciences by 29.1% in the 3rd quarter. KBC Group NV now owns 2,274 shares of the company’s stock worth $72,000 after purchasing an additional 513 shares during the last quarter. Finally, Values First Advisors Inc. bought a new position in IDEAYA Biosciences in the 3rd quarter worth approximately $74,000. Institutional investors own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.